Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. [electronic resource]
Producer: 20010104Description: 2923-9 p. digitalISSN:- 1524-4539
- Abciximab
- Aged
- Antibodies, Monoclonal -- economics
- Drug Therapy, Combination
- Health Care Costs
- Hemorrhage -- prevention & control
- Heparin -- administration & dosage
- Humans
- Immunoglobulin Fab Fragments -- economics
- Middle Aged
- Myocardial Ischemia -- prevention & control
- Myocardial Revascularization -- economics
- Platelet Aggregation Inhibitors -- economics
- Platelet Glycoprotein GPIb-IX Complex -- antagonists & inhibitors
- Platelet Membrane Glycoproteins
- Postoperative Complications -- prevention & control
- Prospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.